Lokesh Sharma pitches CaroRhythm to investors René Bastón of Covenant Venture Capital, Sabriya Stukes, Ph.D. of SOSV, and Doug Hayes of Marblehead & Company.
Date
02/26/2026
Author
Team Coeus
Every 40 seconds, someone in the United States suffers a stroke. But what if stroke risk could be continuously monitored, not just diagnosed after the fact?
In this episode of Capital Calling, Lokesh Sharma, Co-Founder of CaroRhythm, pitches a non-invasive wearable platform designed to transform how stroke risk and carotid artery health are monitored outside the hospital.
CaroRhythm is building a continuous vascular monitoring system focused on the carotid artery—the critical blood vessel supplying the brain—using advanced sensor technology and machine learning-driven analytics to detect changes in blood flow and stroke risk in real time.
Unlike traditional episodic imaging methods such as ultrasound or CT scans, CaroRhythm’s approach aims to provide longitudinal data, enabling clinicians to track trends, identify early warning signs, and intervene before catastrophic events occur. The company is positioned at the intersection of medical devices, digital health, AI diagnostics, and preventative care, targeting secondary stroke prevention and high-risk cardiovascular patients who currently lack continuous outpatient monitoring solutions.
Across the table, investors René Bastón of Covenant Venture Capital, Sabriya Stukes of SOSV, and Doug Hayes of Junto Health and Hubble engage with the pitch as it unfolds.
They probe the regulatory pathway, reimbursement strategy, clinical validation plan, competitive landscape in stroke monitoring and cardiovascular wearables, and whether CaroRhythm can build a defensible, FDA-cleared medical device company in a space dominated by legacy diagnostics.